Current methods in multiplex immunohistochemistry for formalin-fixed tissue samples

Area of Science:

• Pathology
• Immunohistochemistry
• Cancer Research

Background:

• Traditional histopathology methods like H&E staining and chromogenic IHC have limitations in detecting multiple biomarkers and analyzing spatial cell relationships.
• Multiplex immunohistochemistry (mIHC) overcomes these limitations by enabling simultaneous detection of multiple epitopes and detailed spatial analysis in FFPE tissues.
• Characterizing tumor microenvironments is crucial for developing immunotherapies that have transformed cancer treatment.

Purpose of the Study:

• To review the capabilities of multiplex immunohistochemistry (mIHC) methods for analyzing formalin-fixed paraffin-embedded (FFPE) tissues.
• To discuss advancements in mIHC detection techniques, including chromogenic, immunofluorescence, nucleotide-conjugated antibodies, and mass spectrometry.
• To highlight the challenges and future prospects of integrating mIHC into routine clinical diagnostics.

Main Methods:

• Review of modern multiplex immunohistochemistry (mIHC) techniques.
• Discussion of various detection strategies: sequential cyclic labeling, tyramine signal amplification, nucleotide-conjugated antibodies, and mass spectrometry.
• Analysis of challenges including standardization, antibody validation, data analysis, and regulatory aspects.

Main Results:

• mIHC allows simultaneous detection of multiple biomarkers and spatial analysis of cell populations within the tumor microenvironment.
• Advanced techniques like nucleotide-conjugated antibodies and mass spectrometry offer enhanced specificity, quantitative analysis, and extensive biomarker profiling.
• Despite technological progress, routine clinical integration faces hurdles in standardization, validation, data analysis, and regulation.

Conclusions:

• Multiplex immunohistochemistry (mIHC) offers significant advantages over traditional methods for detailed tumor microenvironment analysis.
• Continued automation and digitization in pathology are expected to drive wider adoption of mIHC in clinical practice.
• Successful integration of mIHC promises deeper tumor characterization and improved patient therapy outcomes.